These pharmacological features are relevant to many psychiatric disorders, including PTSD, which exhibit deregulation of multiple neurotransmitter and signaling molecules (e.g., serotonin, NPY, GR, Fkpb5, BDNF, and CRH) and are typically treated by drugs such as fluoxetine that are targeted against specific neurotransmitter systems (Steckler and Risbrough, 2012). Here, BDNF is linked to post-traumatic stress disorder.